Literature DB >> 7608147

Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells.

C Pallard1, F Gouilleux, M Charon, B Groner, S Gisselbrecht, I Dusanter-Fourt.   

Abstract

Interleukin-3 (IL-3)-, erythropoietin (EPO)-, and prolactin (PRL)-induced signal transduction via the JAK/STAT pathway was studied in the IL-3-dependent BAF-3 lymphoid cell line. Transfected cells expressing either the long form of the PRL receptor or the EPO receptor were used. We demonstrated that IL-3, EPO, and PRL activated a transcription factor related to the mammary transcription factor STAT5 but not to STAT1, -2, -3, or -4 as opposed to interferon gamma (IFN gamma) which activated STAT1 in the same cells. Similarly, PRL and EPO activated a STAT5-like factor (STAT5-L) in the rat Nb2 and the human UT7 cells expressing endogenous PRL and EPO receptors, respectively. The hematopoietic STAT5-L activated by IL-3, EPO, or PRL was identified as a 97-kDa tyrosine-phosphorylated protein. These results confer to STAT5 a much broader role than previously suggested.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608147     DOI: 10.1074/jbc.270.27.15942

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.

Authors:  Cristina Hernández; Rafael Simó
Journal:  Endocrine       Date:  2011-12-14       Impact factor: 3.633

Review 2.  STAT signaling in the pathogenesis and treatment of cancer.

Authors:  D A Frank
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

3.  Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells.

Authors:  E Canbay; M Norman; E Kilic; V Goffin; I Zachary
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

4.  Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation.

Authors:  S Chrétien; P Varlet; F Verdier; S Gobert; J P Cartron; S Gisselbrecht; P Mayeux; C Lacombe
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

Review 5.  Prolactin mediated intracellular signaling in mammary epithelial cells.

Authors:  N E Hynes; N Cella; M Wartmann
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

6.  Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain.

Authors:  J G Drachman; K Kaushansky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

7.  Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype.

Authors:  R Moriggl; V Gouilleux-Gruart; R Jähne; S Berchtold; C Gartmann; X Liu; L Hennighausen; A Sotiropoulos; B Groner; F Gouilleux
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

8.  Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

Authors:  Geza Acs; Paul J Zhang; Cindy M McGrath; Peter Acs; John McBroom; Ahmed Mohyeldin; Suzhen Liu; Huasheng Lu; Ajay Verma
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

Review 9.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

10.  Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.

Authors:  Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Journal:  Mol Cell Biol       Date:  2008-09-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.